Connect with us


Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Moves Into A Definitive Agreement With Azevedos



Tetra Bio Pharma Inc (OTCMKTS:TBPMF) has pronounced its entry into a definitive agreement with Azevedos Indústria Farmacêutica. This is an agreement that will see Azevedos engage in the registration, production, and distribution of CAUMZTM.

Terms of the deal

The terms of the deal provide that Tetra will be earning profits and getting milestone payments from sales made.

Azevedos is quite pleased to take up the deal. It outlines that it will do its best to market and distribute CAUMZTM (PPP011) in all the corners of Portugal.

The Chief Regulatory Officer of Tetra, who is also its CEO Guy Chamberland has spoken about the recent development. He has commended Portugal for its strong efforts towards fighting opioid abuse. He has also disclosed that Azevedos is one of the oldest pharmaceutical brands in the country. According to the official, Azevedos has proven its dedication to supporting the country fight opioid abuse that has been reported to claim many lives.

Chamberland says that it is a great honor for them to get the opportunity to collaborate with a progressive partner like Azevedos. He promises to be at the frontline in supporting the company in the sharing of the partner’s great dedication to service. Azevedos has been focusing a great deal of its energy on the development of the best alternatives to opioids.

The official has also spoken about the distribution capabilities of Azevedos. It has a high-end facility in Portugal and others in Tunisia and Mozambique. He asserts that he will lead his company in establishing a strong and progressive working relationship with Azevedos.

Other developments

The terms of the agreement are quite clear, outlining what Tetra gets from the deal. On the other hand, Azevedos has understood all the responsibilities resting on its shoulders.

Tetra Bio Pharma has also today provided an update on the Canadian and US regulatory moves. The FDA had asked for additional information on the company’s CAUMZTM. It is still reviewing to determine the clinical benefits of the product. This company had also submitted some two OTC DIN applications to Health Canada for review. Health Canada has already taken both products through the screening phase, and they have passed.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.